{
    "clinical_study": {
        "@rank": "68769", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "dietary supplement", 
                "arm_group_type": "Active Comparator", 
                "description": "Lactobacillus reuteri DSM 17938"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of a daily supplement consisting of\n      the probiotic bacteria, Lactobacillus reuteri, on the digestive health among persons 65\n      years and older."
        }, 
        "brief_title": "Efficacy of a Dietary Supplementation With Lactobacillus Reuteri for Digestive Health in an Elderly Population", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Constipation", 
            "Diarrhea", 
            "Indigestion", 
            "Reflux", 
            "Abdominal Pain"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Abdominal Pain", 
                "Constipation", 
                "Diarrhea", 
                "Dyspepsia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The overall purpose of the study is to investigate the effect of daily supplementation,\n      during a three months period, of L. reuteri on digestive health in an elderly Swedish\n      population, residing in the municipality of \u00d6rebro. In addition an extensive screening of\n      the study population in regard of overall health status, functionality and well-being as\n      well as the composition of the gut microbiome will be assessed prior study start through the\n      collection of baseline data"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 65 years\n\n          -  Informed consent signed by study participant or legal guardian\n\n        Exclusion Criteria:\n\n          -  Known gastrointestinal disease, with strictures, malignance's and ischemia.\n\n          -  Inflammatory bowel diseases (IBD)\n\n          -  Participation in other clinical trials in the past three months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837940", 
            "org_study_id": "2012/309"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Galactooligosaccharide (GOS) and rhamnose in a powder formulation", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "dietary supplement", 
                "description": "Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation", 
                "intervention_name": "Lactobacillus reuteri DSM 17938", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "\u00d6rebro", 
                    "country": "Sweden", 
                    "state": "N\u00e4rke", 
                    "zip": "701 82"
                }, 
                "name": "\u00d6rebro University"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of a Dietary Supplementation With Lactobacillus Reuteri DSM 17938 for Digestive Health in an Elderly Population", 
        "other_outcome": [
            {
                "description": "Mood changes will be assessed through the questionnaire hospital anxiety and depression scale (HADs)", 
                "measure": "Change in mood during the 3month intervention period", 
                "safety_issue": "No", 
                "time_frame": "at baseline, 2months and 3monts/study end"
            }, 
            {
                "description": "Quality of life will be assessed through the EuroQol questionnaire.", 
                "measure": "Change in quality of life during the 3-month intervention period", 
                "safety_issue": "No", 
                "time_frame": "at baseline, at baseline, 2months and 3monts/study end"
            }
        ], 
        "overall_official": {
            "affiliation": "\u00d6rebro Universitet", 
            "last_name": "Robert Jan Brummer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Sweden: The ethical review board; Regionala etikpr\u00f6vningsn\u00e4mnden i Uppsala"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Gastrointestinal discomfort will be assessed through the gastrointestinal symptoms rating score (GSRS), a clinical rating scale for gastrointestinal symptoms. The GSRS includes 15 symptoms and uses a 7-point Likert scale in which 1 represents the most positive option and 7 the most negative.", 
            "measure": "Change from baseline Gastrointestinal symptoms to 3months", 
            "safety_issue": "No", 
            "time_frame": "Baseline, at 2 months and at 3months/study end"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837940"
        }, 
        "responsible_party": {
            "investigator_affiliation": "\u00d6rebro University, Sweden", 
            "investigator_full_name": "Robert Brummer", 
            "investigator_title": "Professor and Dean", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Intestinal motility regulating substances (e.g anti-diarrheal and anti-constipation medication)", 
            "measure": "Change in use of intestinal motility regulating substances during the 3-month intervention period", 
            "safety_issue": "No", 
            "time_frame": "at baseline and end of study ( 3months)"
        }, 
        "source": "\u00d6rebro University, Sweden", 
        "sponsors": {
            "collaborator": {
                "agency": "BioGaia AB", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "\u00d6rebro University, Sweden", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}